INCY241220P110000
- 0.00
- 0.000.00%
Incyte Newsroom
Oppenheimer Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $82
Stifel Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $75
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $86
BMO Capital Maintains Incyte(INCY.US) With Sell Rating, Maintains Target Price $52
TD Cowen Reaffirms Their Buy Rating on Incyte (INCY)
Stifel Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $75
Stifel Nicolaus Sticks to Their Hold Rating for Incyte (INCY)
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Incyte (INCY) and Prenetics Group (PRE)
RBC Capital Sticks to Its Hold Rating for Incyte (INCY)
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Raises Target Price to $86
TD Cowen Remains a Buy on Incyte (INCY)
TD Cowen Adjusts Price Target on Incyte to $86 From $80, Keeps Buy Rating
Incyte Is Maintained at Sector Perform by RBC Capital
BofA Securities Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $86
Incyte Analyst Ratings
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $80
A Quick Look at Today's Ratings for Incyte(INCY.US), With a Forecast Between $52 to $86
TD Cowen Remains a Buy on Incyte (INCY)
Incyte's Strategic Growth Potential and Rich Pipeline Underpin Buy Rating at $86 Target
RBC Cuts Price Target on Incyte to $74 From $80, Keeps Sector Perform Rating